DFTX
Definium Therapeutics, Inc. · Healthcare · Market cap $4.8B
Insiders sold $3.0M net in the last 90 days ·5 sellers, 0 buyers· 6 of 6 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 30, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$6.4M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Sep 30, 2026
Karlin Daniel
Definium Therapeutics, Inc. (DFTX) has 42 SEC Form 4 filings (43 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Sep 30, 2026.
Inside the rolling window, 5 insiders at Definium Therapeutics, Inc. reported no open-market purchases and 14 open-market sales totaling $6.4M. The most active filer is Chief Executive Officer Barrow Robert with 4 filings. Insiders have net sold $5.6M over the trailing 6 months. The most recent open-market filing is a sale of 10,853 shares by Chief Medical Officer Karlin Daniel, dated Sep 25, 2026, worth $397K.
- Industry:Biotechnology
- CEO:Robert Barrow
- Employees:106
- HQ:New York, NY, US
- IPO:2016-11-15
| Source | |||||||
|---|---|---|---|---|---|---|---|
Karlin DanielFirst in 3 months | Chief Medical Officer | Sale | 10,853 | $397K | Sep 30 | -6.3% | SEC ↗ |
| Chief Executive Officer | Sale | 31,550 | $1.2M | Sep 30 | -6.3% | SEC ↗ | |
Wiley Matthew T.First in 3 months | Chief Commercial Officer | Sale | 3,097 | $113K | Sep 30 | -6.3% | SEC ↗ |
Sullivan MarkFirst in 3 months | Chief Legal Officer | Sale | 14,051 | $514K | Sep 30 | -6.3% | SEC ↗ |
Roberts BrandiFirst in 3 months | Chief Financial Officer | Sale | 3,377 | $123K | Sep 30 | -6.3% | SEC ↗ |
| Chief Executive Officer | Sale | 19,023 | $722K | Sep 5 | -6.7% | SEC ↗ | |
Wiley Matthew T.First filing | Chief Commercial Officer | Sale | 2,867 | $129K | Jun 26 | -20.6% | SEC ↗ |
Barrow RobertFirst in 3 months | Chief Executive Officer | Sale | 29,208 | $1.3M | Jun 26 | -20.6% | SEC ↗ |
Sullivan MarkFirst in 3 months | Chief Legal Officer | Sale | 13,008 | $586K | Jun 26 | -20.6% | SEC ↗ |
Karlin DanielFirst in 3 months | Chief Medical Officer | Sale | 10,035 | $452K | Jun 26 | -20.6% | SEC ↗ |
Roberts BrandiFirst filing | Chief Financial Officer | Sale | 3,013 | $136K | Jun 26 | — | SEC ↗ |
| Chief Medical Officer | Sale | 8,018 | $148K | Mar 26 | — | SEC ↗ | |
| Chief Legal Officer | Sale | 10,702 | $198K | Mar 26 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 24,431 | $451K | Mar 26 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does DFTX have?
Definium Therapeutics, Inc. (DFTX) has 42 SEC Form 4 filings (43 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Sep 30, 2026.
When was the most recent SEC Form 4 filing for DFTX?
The most recent Form 4 filing for DFTX on Tracefour is dated Sep 30, 2026.
Who is the most active insider at DFTX?
The most active SEC Form 4 filer at DFTX in the rolling window is Chief Executive Officer Barrow Robert, with 4 filings.
What is the net insider flow at DFTX over the last 6 months?
Over the trailing 180 days, insiders at DFTX have net sold $5.6M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at DFTX in the current window?
Inside the rolling window, insiders at DFTX bought $0 and sold $6.4M based on SEC Form 4 filings.
Can I get alerts for DFTX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Definium Therapeutics, Inc. (DFTX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Definium Therapeutics, Inc. is in the Healthcare sector.